Childers, Schlueter & Smith (CSS) has filed the first Dupixent lawsuit in the state of Georgia, marking an important development in emerging litigation involving a widely prescribed eczema and asthma medication.
The federal complaint alleges that Dupixent, also known by its generic name dupilumab, may be linked to cutaneous T-cell lymphoma (CTCL), a rare form of non-Hodgkin lymphoma that can initially present with symptoms similar to eczema. According to the lawsuit, the similarities between eczema and CTCL symptoms may have delayed diagnosis and treatment for some patients who were prescribed Dupixent.
Dupixent, approved by the FDA in 2017, is an injectable biologic drug manufactured by Sanofi and Regeneron and is commonly prescribed for eczema, asthma, and other inflammatory conditions. While the manufacturers have stated that the drug has a favorable safety profile, Dupixent lawsuits allege that patients and healthcare providers were not adequately warned about a potential cancer risk.
About the Dupixent Lawsuit Filed in Georgia
In the Georgia case, the plaintiff, Wanda Nalls, alleges that she developed cutaneous T-cell lymphoma after using Dupixent to treat eczema. The lawsuit names Regeneron Pharmaceuticals and Sanofi as defendants.
According to the complaint, Nalls was diagnosed with CTCL a few months after starting the medication and subsequently underwent multiple rounds of radiation and chemotherapy. The filing asserts that a “strong and consistent causal relationship” between Dupixent and CTCL exists based on a growing number of adverse event reports and published case studies, and that the defendants failed to appropriately revise the U.S. prescribing information despite mounting evidence of risk. The plaintiff further alleges that earlier warnings could have led to different treatment decisions and earlier medical intervention.
Nalls is represented by C. Andrew Childers of Childers, Schlueter & Smith, together with co-counsel, bringing experience in complex pharmaceutical litigation to this new area of dangerous drug claims.
How CSS Handles Dangerous Drug Cases
Childers, Schueter & Smith has extensive experience representing individuals harmed by dangerous and defective pharmaceutical products. Our firm’s attorneys regularly handle complex mass tort and drug injury cases involving allegations such as failure to warn, negligent misrepresentation, and defective drug design. We have a long history of standing up to pharmaceutical manufacturers when patient safety is compromised. When medications cause harm, patients deserve answers, transparency, and accountability.
This Dupixent case exemplifies the firm’s ongoing commitment to protecting patients and holding drug manufacturers accountable when safety concerns are alleged to have been ignored or minimized.
As Dupixent litigation develops nationwide, CSS expects additional cases may be filed as more patients learn about the potential risks and evaluate their legal options. Our firm will continue monitoring regulatory developments, scientific research, and court proceedings related to Dupixent.
Individuals who were prescribed Dupixent and later diagnosed with CTCL or another form of lymphoma are encouraged to seek legal guidance to better understand their rights. For more information, call 1-800-641-0098, use our live online chat, or contact the firm online for a free consultation.
